| Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results AD Shapiro, P Angchaisuksiri, J Astermark, G Benson, G Castaman, ... Blood, The Journal of the American Society of Hematology 134 (22), 1973-1982, 2019 | 145 | 2019 |
| Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients R Ljung, G Auerswald, G Benson, G Dolan, A Duffy, C Hermans, ... European journal of haematology 102 (2), 111-122, 2019 | 120 | 2019 |
| Pain and pain management in haemophilia G Auerswald, G Dolan, A Duffy, C Hermans, V Jimenez-Yuste, R Ljung, ... Blood Coagulation & Fibrinolysis 27 (8), 845-854, 2016 | 106 | 2016 |
| Results from a large multinational clinical trial (guardian™ 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A … SR Lentz, M Misgav, M Ozelo, SZ Šalek, D Veljkovic, M Recht, ... Haemophilia 19 (5), 691-697, 2013 | 102 | 2013 |
| Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management G Benson, G Auerswald, G Dolan, A Duffy, C Hermans, R Ljung, M Morfini, ... Blood Transfusion 16 (6), 535, 2018 | 101 | 2018 |
| Practical aspects of extended half-life products for the treatment of haemophilia T Lambert, G Benson, G Dolan, C Hermans, V Jiménez-Yuste, R Ljung, ... Therapeutic advances in hematology 9 (9), 295-308, 2018 | 101 | 2018 |
| Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers D Kastelan, T Dusek, I Kraljevic, O Polasek, Z Giljevic, M Solak, SZ Salek, ... Endocrine 36, 70-74, 2009 | 93 | 2009 |
| Haemophilia B: where are we now and what does the future hold? G Dolan, G Benson, A Duffy, C Hermans, V Jiménez-Yuste, T Lambert, ... Blood reviews 32 (1), 52-60, 2018 | 73 | 2018 |
| Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future V Jiménez-Yuste, G Auerswald, G Benson, T Lambert, M Morfini, E Remor, ... Blood transfusion 12 (3), 314, 2014 | 72 | 2014 |
| Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice G Benson, G Auerswald, I Elezović, T Lambert, R Ljung, M Morfini, ... European journal of haematology 88 (5), 371-379, 2012 | 67 | 2012 |
| Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study I Radman, J Kovacevic-Metelko, I Aurer, D Nemet, S Zupancic-Salek, ... Croatian medical journal 43 (5), 555-560, 2002 | 60 | 2002 |
| Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome S Zupančić Šalek, V Sokolić, T Visković, J Šanjug, M Šimić, M Kaštelan Acta haematologica 108 (3), 162-163, 2002 | 60 | 2002 |
| Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity JN Mahlangu, KN Weldingh, SR Lentz, S Kaicker, FA Karim, T Matsushita, ... Journal of thrombosis and haemostasis 13 (11), 1989-1998, 2015 | 55 | 2015 |
| First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational … W Kreuz, C Escuriola Ettingshausen, V Vdovin, N Zozulya, O Plyushch, ... Haemophilia 22 (1), 87-95, 2016 | 54 | 2016 |
| Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B K Kavakli, L Smith, K Kuliczkowski, J Korth‐Bradley, CW You, J Fuiman, ... Haemophilia 22 (3), 381-388, 2016 | 48 | 2016 |
| Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII S Zupancic-Šalek, J Kovacevic-Metelko, I Radman Blood coagulation & fibrinolysis 16 (4), 239-244, 2005 | 40 | 2005 |
| Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial EV De Paula, K Kavakli, J Mahlangu, Y Ayob, SR Lentz, M Morfini, ... Journal of thrombosis and haemostasis 10 (1), 81-89, 2012 | 38 | 2012 |
| Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs E Santagostino, M Morfini, GKH Auerswald, GM Benson, SZ Šalek, ... Haemophilia 15 (5), 983-989, 2009 | 36 | 2009 |
| Hemophilia treatment in 2021: Choosing the” optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians C Hermans, D Noone, G Benson, G Dolan, H Eichler, V Jiménez-Yuste, ... Blood reviews 52, 100890, 2022 | 35 | 2022 |
| Decreasing risk of viral transfusion-transmitted diseases in Croatia. D Grgicević, M Balija, D Pirc-Tiljak, I Mihaljević, I Gjenero-Margan, ... Croatian Medical Journal 41 (2), 191-196, 2000 | 34 | 2000 |
